Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Aldara

(Imiquimod)

ApprovedSmall molecule

BBausch Health Americas, Inc.

Imiquimod is used to treat certain skin conditions caused by viruses, including genital warts and a type of skin cancer called basal cell carcinoma. It works by boosting the immune system to help your body fight off these conditions.[2] Aldara is currently approved and in use across 31 indications[4].[1]

Aldara is one of 389 small molecule programs targeting Hemangioma. It is currently in Approved.

31

Indications

101

Total Trials

6

Active Trials

388

Competitors

2

FDA Applications

NDA/BLA/ANDA regulatory filings

10

Patents

Pipeline

Status by Indication[4][1]

Indication

HemangiomaApproved

Viral DiseaseActive, not recruiting

Extramammary Paget DiseaseApproved

Bowen Disease of the SkinApproved

Oral Squamous Cell CarcinomaApproved

Basal Cell CarcinomaCompleted

CheilitisApproved

Vulvar CarcinomaActive, not recruiting

Cutaneous T-Cell LymphomaApproved

Cutaneous MelanomaApproved

HemangiomaApproved

Approved

Viral DiseaseApproved

Active, not recruiting

Extramammary Paget DiseaseApproved

Approved

Bowen Disease of the SkinApproved

Approved

Oral Squamous Cell CarcinomaApproved

Approved

Basal Cell CarcinomaApproved

Completed

CheilitisApproved

Approved

Vulvar CarcinomaPreclinical

Active, not recruiting

Cutaneous T-Cell LymphomaApproved

Approved

Cutaneous MelanomaApproved

Approved

Showing 10 of 31 indications

Competition

Competitive Landscape

332 competitors in Treatment

#DrugCompanyPhaseTrials

Aldara

BBausch Health Americas, Inc.

Dexilant

Alfenta

Jazz Pharmaceuticals

Lamprene

Emtriva

Foscavir

CClinigen, Inc.

Clomid

Aurlumyn

BBTG International Inc.

Lotemax

Norpramin

VValidus Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Cervical Intraepithelial Neoplasia

NCT05405270

Q2 2027

Phase 1Active, not recruiting

Metastatic Colorectal Adenocarcinoma

NCT02600949

Q4 2027

Phase 1/2Recruiting

Treatment

NCT07210775

Q4 2028

Phase 1/2Recruiting

Basal Cell Carcinoma

NCT07251413

Post-ApprovalRecruiting

Biomarkers

NCT06356012

Clinical

Trials by Indication[1]

Treatment7 trials

Efficacy of Tazarotene in Treatment of Verruca Plana

Unknown status·ZZagazig University·Phase 2·NCT05314127·80 enrolled

Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol

Unknown status·EErasmus Medical Center·Phase 3·NCT02669459·433 enrolled

Aldara for the Treatment of Large and/or Multiple sBCC

Completed·MMEDA Pharma GmbH & Co. KG·Phase 3·NCT00189280·111 enrolled

Show 4 more trials

Imiquimod Treatment of CIN Lesions

Terminated·MMaastricht University Medical Center·Phase 3·NCT02329171·9 enrolled

Topical Imiquimod Treatment of Oral Dysplasia

Recruiting·UUniversity of Southern California·Phase 1/2·NCT07210775·20 enrolled

The Effects of Aldara as an Adjunct to Laser Treatment

Terminated·HHenry Vasconez·Phase 2·NCT00979550·7 enrolled

Imiquimod Treatment of High-grade CIN

Unknown status·MMaastricht University Medical Center·N/A·NCT02917746·120 enrolled

Actinic Keratoses7 trials

Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)

Completed·MMEDA Pharma GmbH & Co. KG·Phase 4·NCT01453179·221 enrolled

Gene and Protein Expression Profiles After Treatment of Actinic Keratoses

Unknown status·IIsmail Gögenur·Phase 2·NCT05740969·48 enrolled

Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy

Terminated·—·Phase 4·NCT01203878·21 enrolled

Show 4 more trials

A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ

Completed·MMEDA Pharma GmbH & Co. KG··NCT00189254·72 enrolled

Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)

Completed·GGraceway Pharmaceuticals, LLC·Phase 3·NCT00603798·490 enrolled

Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)

Completed·GGraceway Pharmaceuticals, LLC·Phase 3·NCT00605176·479 enrolled

Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses

Completed·MMEDA Pharma GmbH & Co. KG·Phase 4·NCT00777127·258 enrolled

Basal Cell Carcinoma7 trials

Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma

Completed·UUniversity Hospital Tuebingen·Phase 4·NCT00204555·100 enrolled

Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage

Completed·WWake Forest University·Phase 4·NCT00314756·15 enrolled

A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma

Completed·MMelanoma Institute Australia·Phase 2·NCT03534947·16 enrolled

Show 4 more trials

Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma

Recruiting·IInstituto Oncológico Dr Rosell·Phase 1/2·NCT07251413·18 enrolled

A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base

Unknown status·UUniversity of Glasgow·N/A·NCT00463359·50 enrolled

A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma

Completed·MMEDA Pharma GmbH & Co. KG·Phase 3·NCT00189241·160 enrolled

Real-world Evaluation of (Non-invasive) Diagnostic and Treatment Strategies in Low-Risk Basal Cell Carcinoma: a Prospective Cohort Study

Completed·MMaastricht University Medical Center··NCT06252857·142 enrolled

Melanoma6 trials

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Completed·CCraig L Slingluff, Jr·Phase 1·NCT00118313

Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin

Completed·UUniversity of Oklahoma·Phase 1·NCT00453050·11 enrolled

Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma

Completed·UUniversity of Virginia·Phase 1·NCT01264731·4 enrolled

Show 3 more trials

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

Completed·MMayo Clinic·Phase 1·NCT03276832·7 enrolled

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00273910·104 enrolled

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

Completed·LLudwig Institute for Cancer Research·Phase 1·NCT00142454·9 enrolled

Actinic Keratosis6 trials

IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis

Unknown status·MMaastricht University Medical Center·Phase 4·NCT02281682·624 enrolled

The Real Life Topical Field Treatment of Actinic Keratosis Study

Completed· LEO Pharma logo

LEO Pharma··NCT02362152·1,168 enrolled

Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis

Completed·AActavis Inc.·Phase 3·NCT00948428·462 enrolled

Show 3 more trials

Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis

Completed·GGraceway Pharmaceuticals, LLC·Phase 4·NCT00116649·551 enrolled

Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head

Completed·MMoberg Pharma AB·Phase 2·NCT01611480

Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery

Completed·GGraceway Pharmaceuticals, LLC·Phase 3·NCT00894647·247 enrolled

52 more indications

Cervical Intraepithelial Neoplasia5 trials

Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment

Recruiting·CCatharina Ziekenhuis Eindhoven··NCT05405270·410 enrolled

Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia

Terminated·MMedical University of Vienna·Phase 3·NCT01283763·95 enrolled

Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00788164·75 enrolled

Show 2 more trials

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00988559·132 enrolled

Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03196180·13 enrolled

Breast Cancer4 trials

Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases

Completed·NNYU Langone Health·Phase 2·NCT00899574·10 enrolled

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

Completed·UUniversity of Washington·Phase 2·NCT00821964·15 enrolled

Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases

Completed·NNYU Langone Health·Phase 1/2·NCT01421017·31 enrolled

Show 1 more trial

Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer

Terminated·WWashington University School of Medicine·Phase 1·NCT03982004·1 enrolled

Influenza4 trials

Intradermal Influenza Vaccine in the Young

Completed·TThe University of Hong Kong·Phase 3·NCT02103023·160 enrolled

Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients

Terminated·—·Phase 2·NCT00596336·24 enrolled

Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children

Unknown status·TThe University of Hong Kong·N/A·NCT05315024·72 enrolled

Show 1 more trial

Intradermal Trivalent Influenza Vaccine With Imiquimod

Completed·TThe University of Hong Kong·N/A·NCT01508884·93 enrolled

Glioma2 trials

Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas

Completed·FFrank Lieberman·Phase 1·NCT01678352·19 enrolled

Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT01400672·8 enrolled

Skin Cancer2 trials

Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer

Completed·—·Phase 1·NCT00079300

Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer

Completed·QQueen's Medical Center·Phase 3·NCT00066872·500 enrolled

Dendritic Cell2 trials

Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT01171469·8 enrolled

Dendritic Cell Vaccine for Children and Adults With Sarcoma

Completed·MMacarena De La Fuente, MD·Phase 1·NCT01803152·19 enrolled

Vulvar Intraepithelial Neoplasia2 trials

Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment

Completed·MMedical University of Vienna·Phase 2·NCT00941811·5 enrolled

Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia

Completed·MMedical University of Graz·Phase 3·NCT01861535·110 enrolled

Safety and Efficacy2 trials

Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses

Completed·UUniversity of British Columbia·Phase 3·NCT00175643·20 enrolled

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

Completed·AActavis Inc.·Phase 3·NCT02120898·467 enrolled

Genital Warts2 trials

Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts

Completed·GGraceway Pharmaceuticals, LLC·Phase 3·NCT00674739·470 enrolled

Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts

Completed·MMEDA Pharma GmbH & Co. KG·Phase 4·NCT00189293·128 enrolled

Malignant Glioma1 trial

Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma

Completed·MMacarena De La Fuente, MD·Phase 1·NCT01808820·20 enrolled

Carcinoma1 trial

Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix

Completed·UUnited States Naval Medical Center, San Diego·Phase 2/3·NCT02130323·22 enrolled

Ependymoma1 trial

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

Terminated·JJames Felker·Phase 1·NCT01795313·23 enrolled

Inflammation1 trial

Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation

Completed·CCONRAD·Phase 2·NCT01593124·20 enrolled

Biochemical Recurrence1 trial

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

Unknown status·UUniversity Hospital Tuebingen·Phase 1/2·NCT02452307·36 enrolled

Tics1 trial

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453

Completed· Novartis logo

Novartis·Phase 1·NCT02052687·41 enrolled

Psoriasis1 trial

Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis

Terminated·VVA Office of Research and Development·N/A·NCT00470392·9 enrolled

IgAN1 trial

Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers

Completed·MMaruho Co., Ltd.·Phase 1·NCT03071679·16 enrolled

Immune Response1 trial

Comparing Immune Responses to Topical Imiquimod

Terminated·UUniversity of California, Davis··NCT04809662·6 enrolled

Recurrent1 trial

Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva

Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT00504023·8 enrolled

Cutaneous Leishmaniasis1 trial

Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis

Completed·DDrugs for Neglected Diseases·Phase 3·NCT00257530·80 enrolled

Anal Cancer1 trial

Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

Completed·AAIDS Malignancy Consortium·Phase 3·NCT02135419·4,446 enrolled

Photoaging1 trial

Photoaging Treatment With Imiquimod

Completed·—·N/A·NCT01935310·17 enrolled

Anal Dysplasia1 trial

Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV

Withdrawn·UUnited States Naval Medical Center, San Diego·Phase 4·NCT01663558

AIN1 trial

Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks

Completed·UUniversity of California, Irvine·N/A·NCT00585247·27 enrolled

Patients With Solid Tumors1 trial

HER2-Peptide Vaccination of Patients With Solid Tumors

Completed·TTechnical University of Munich·Phase 1·NCT02276300·2 enrolled

Cervical Cancer1 trial

Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00031759·57 enrolled

Skin Lesions1 trial

Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

Completed·AAIDS Malignancy Consortium·Phase 3·NCT02059499·91 enrolled

Adult1 trial

H5N1 With or Without Topical Aldara in Healthy Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03472976·50 enrolled

Glioblastoma1 trial

Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

Terminated·IImmatics Biotechnologies GmbH·Phase 1·NCT01403285·6 enrolled

Age1 trial

Topical 5% Imiquimod Cream for Vulvar Paget's Disease

Completed·UUniversity Medical Center Nijmegen·Phase 3·NCT02385188·25 enrolled

Solid Malignancies1 trial

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

Terminated·KKiromic BioPharma Inc.·Phase 1/2·NCT02224599·3 enrolled

Hepatitis B1 trial

Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen

Unknown status·—·Phase 2·NCT05028322·60 enrolled

Double-blind1 trial

A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects

Completed·MMoberg Pharma AB·Phase 1·NCT01567683

Combination Therapy1 trial

Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna

Completed·UUniversity of Utah·N/A·NCT00707174·90 enrolled

Lentigo1 trial

Effect of Topical Imiquimod on Lentigo Maligna

Completed·JJerry Marsden·Phase 4·NCT01161888·30 enrolled

Plantar Wart1 trial

Comparison of Five Treatments in Patients With Plantar Warts

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT01059110·358 enrolled

Mycosis Fungoides1 trial

Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides

Recruiting·NNorthwestern University·Phase 1·NCT05838599·25 enrolled

Clinical Trial1 trial

Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions

Completed·—·Phase 2·NCT03233412·90 enrolled

Cervical Lesion1 trial

Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)

Completed·YYale University·Phase 2·NCT02864147·134 enrolled

Glioblastoma Multiforme1 trial

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Completed·SStemline Therapeutics, Inc.·Phase 1/2·NCT02078648·74 enrolled

Biomarkers1 trial

Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod

Recruiting·—·Phase 4·NCT06356012·96 enrolled

Radiotherapy1 trial

Radiotherapy or Imiquimod in Complex Lentigo Maligna

Completed·MMelanoma and Skin Cancer Trials Limited·Phase 3·NCT02394132·126 enrolled

Head and Neck1 trial

Topical Imiquimod for Bowen's Disease of the Head and Neck

Unknown status·—·Phase 2/3·NCT00384124·50 enrolled

CTCL1 trial

CTCL Directed Therapy

Unknown status·JJames J. Peters Veterans Affairs Medical Center·Phase 1·NCT03116659·8 enrolled

Recurrence1 trial

Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna

Unknown status·MMedical University of Graz·Phase 2/3·NCT01088737·60 enrolled

Prostate Cancer1 trial

Pilot Study of DRibble Vaccine for Prostate Cancer Patients

Completed·UUbiVac·Phase 1·NCT02234921·3 enrolled

Adjuvant1 trial

Coadministration of GA2 Sporozoites With Adjuvants

Unknown status·LLeiden University Medical Center·Phase 1·NCT05468606·45 enrolled

Non-Small Cell Lung Cancer1 trial

Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer

Completed·UUbiVac·Phase 2·NCT01909752·12 enrolled

First Line Therapy1 trial

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

Completed·UUniversity Hospital Tuebingen·Phase 2·NCT02802943·56 enrolled

Metastatic Colorectal Adenocarcinoma1 trial

Pilot Study of the Feasibility and Safety of a Personalized Peptide Vaccine in Patients With Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT02600949·119 enrolled

Colorectal Cancer1 trial

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

Completed·TToray Industries, Inc·Phase 1·NCT03872947·138 enrolled

Ovarian Cancer1 trial

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With GM-CSF and Imiquimod

Terminated·BBeth Israel Deaconess Medical Center·Phase 2·NCT00799110·15 enrolled

Regulatory

FDA Approval Timeline[5]

Feb 27, 1997

ALDARA

NDA NDA020723

Jul 15, 2011

ZYCLARA

NDA NDA022483

Sources

References

[1]
ClinicalTrials.gov — 101 trial records for Imiquimod. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Aldara drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Imiquimod compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Imiquimod. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022483). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Aldara. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Bausch Health Americas, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Toll-Like Receptor 7 Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: BBausch Health Americas, Inc.

Patent Landscape[6]

Patent Cliff

Aug 18, 2029

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8598196Aug 18, 2029

10238645Aug 18, 2029

8299109Dec 11, 2029

11318130Dec 11, 2029

8236816Dec 11, 2029

5 more patents

8222270Dec 11, 2029

10238644Dec 11, 2029

10918635Apr 30, 2030

11850245Apr 30, 2030

11202752Apr 30, 2030

Related News